A phase I, open label, non-randomised study to evaluate the pharmacokinetics and safety of Pralatrexate in patients with relapsed refractory advanced solid tumors and lymphoma with mild, moderate and severe renal impairment

Trial Profile

A phase I, open label, non-randomised study to evaluate the pharmacokinetics and safety of Pralatrexate in patients with relapsed refractory advanced solid tumors and lymphoma with mild, moderate and severe renal impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 14 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top